Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation. (15th July 2019) - Ighilahriz, M.; Benfodda, M.; Sharpe, H.; Soufir, N.; Mourah, S.; Dumaz, N.; Battistella, M.; Savina, A.; Bouquet, F.; Nikolaev, S.; Basset‐Seguin, N.